Clinical Trials Browser

OTHER_GOV × Meningeal Carcinomatosis × Clear all

NCT05805631 2026-03-24

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT07264569 2025-12-04

Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001

Phase 1/2 Recruiting

Meningeal Carcinomatosis

NCT06971406 2025-05-14

FLAME-1

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06441045 2024-06-04

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Phase 2 Not yet recruiting

Meningeal Carcinomatosis

NCT04778800 2021-08-31

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Phase NA Unknown

Brain Neoplasms, Meningeal Carcinomatosis